Sugi Predict

Sugi Predict / Compounds / SCHEMBL1775616

SCHEMBL1775616

SCHEMBL1775616

C[C@H]1COCc2nc3c[n+]([O-])c4ccc(OCc5ccccc5)cc4c3n21

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ DYRK1A Q13627 1/20 0.35
▸ GRM5 P41594 3/20 0.35
▸ HRH3 Q9Y5N1 3/20 0.34
▸ MAOB P27338 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1773836 0.78 CYP3A4 (0.39) NPC1RAB9AGRM5MAOBKDM4E
SCHEMBL1774146 0.75 PARP14 (0.39) NPC1RAB9ADYRK1AGRM5MAOB
SCHEMBL1773453 0.75 GRM5 (0.35) GRM5
SCHEMBL1486543 0.75 MEN1 (0.44) NPC1RAB9AMEN1KMT2ADYRK1A
SCHEMBL1486562 0.72 RAB9A (0.40) NPC1RAB9AMEN1KMT2AMAOB
SCHEMBL1486536 0.72 MEN1 (0.41) NPC1RAB9AMEN1KMT2ADYRK1A
SCHEMBL1486545 0.72 RAB9A (0.41) NPC1RAB9AMEN1KMT2ADYRK1A
SCHEMBL1486743 0.70 L3MBTL1 (0.39) NPC1RAB9AMEN1KMT2ADYRK1A
SCHEMBL1486597 0.69 HRH3 (0.41) NPC1RAB9AMEN1KMT2ADYRK1A
SCHEMBL1486723 0.69 TLR7 (0.48) NPC1RAB9AMEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546383-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-10-01 — — US disclosed
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2012-09-13 — — US disclosed
EP-1831226-B1 CHIRAL TETRACYCLIC COMPOUNDS INDUCING INTERFERON BIOSYNTHESIS 3M INNOVATIVE PROPERTIES CO (US) 2012-08-08 — — EP disclosed
US-8207162-B2 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-06-26 — — US disclosed
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS 3M INNOVATIVE PROPERTIES COMPANY 2011-08-25 — — US disclosed
US-7943609-B2 Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides 3M INNOVATIVE PROPRERTIES COMPANY (US) 2011-05-17 — — US disclosed
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269192-A1 Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds IFNAR1, IFNG, IL4 NPC1 1586/4885RAB9A 1298/4885MEN1 2108/4885
US-20120232057-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 NPC1 1558/4885RAB9A 1331/4885MEN1 2062/4885
US-20110207725-A1 CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS IFNAR1, IFNG, IL4 NPC1 1586/4885RAB9A 1298/4885MEN1 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.